Literature DB >> 23207606

Discovering the route from inflammation to pancreatic cancer.

N Momi1, S Kaur, S R Krishn, S K Batra.   

Abstract

Pancreatic cancer (PC) remains a complex malignancy with the worst prognosis, lack of early diagnostic symptoms and resistance to conventional chemo- and radiotherapies. A better understanding of the etiology and early developmental events of PC requires profound attention. The evolution of fully blown PC from initial pancreatic injury is a multi-factorial phenomenon with a series of sequential events. The initial acute infection or tissue damage triggers inflammation that, in conjunction with innate immunity, establishes a state of homeostasis to limit harm to the body. Recurrent pancreatic injuries due to genetic susceptibility, smoking, unhealthy diet, and alcohol abuse induces a pro-inflammatory milieu, consisting of various types of immune cells, cytokines, chemokines, growth factors and restructured extracellular matrix, leading to prolonged inflammatory/chronic conditions. Cells having sustained DNA damage and/or mutagenic assault take advantage of this prolonged inflammatory response and aid in the initiation and development of neoplastic/fibrotic events. Eventually, many tumor-stromal interactions result in a chaotic environment accompanied by a loss of immune surveillance and repair response, thereby leading to PC. A better understanding of the inflammatory markers defining this "injury-inflammation-cancer" pathway would help to identify novel molecular targets for early screening and therapeutic intervention for this lethal malignancy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23207606      PMCID: PMC3556910     

Source DB:  PubMed          Journal:  Minerva Gastroenterol Dietol        ISSN: 1121-421X


  108 in total

Review 1.  The pancreatic stellate cell: a star on the rise in pancreatic diseases.

Authors:  M Bishr Omary; Aurelia Lugea; Anson W Lowe; Stephen J Pandol
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

2.  Smoking is related to pancreatic fibrosis in humans.

Authors:  Erwin J M van Geenen; Mark M Smits; Tim C M A Schreuder; Donald L van der Peet; Elisabeth Bloemena; Chris J J Mulder
Journal:  Am J Gastroenterol       Date:  2011-05-17       Impact factor: 10.864

3.  Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.

Authors:  Rachel F Gabitass; Nicola E Annels; Deborah D Stocken; Hardev A Pandha; Gary W Middleton
Journal:  Cancer Immunol Immunother       Date:  2011-06-05       Impact factor: 6.968

4.  Obesity increases the risk of UV radiation-induced oxidative stress and activation of MAPK and NF-kappaB signaling.

Authors:  Santosh K Katiyar; Syed M Meeran
Journal:  Free Radic Biol Med       Date:  2006-10-28       Impact factor: 7.376

Review 5.  Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.

Authors:  G Boden
Journal:  Diabetes       Date:  1997-01       Impact factor: 9.461

6.  Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer.

Authors:  Suresh T Chari; Cynthia L Leibson; Kari G Rabe; Lawrence J Timmons; Jeanine Ransom; Mariza de Andrade; Gloria M Petersen
Journal:  Gastroenterology       Date:  2007-10-26       Impact factor: 22.682

Review 7.  Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.

Authors:  Y-F Chen; P Jobanputra; P Barton; S Bryan; A Fry-Smith; G Harris; R S Taylor
Journal:  Health Technol Assess       Date:  2008-04       Impact factor: 4.014

8.  Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.

Authors:  Tomislav Dragovich; Howard Burris; Patrick Loehrer; Daniel D Von Hoff; Sherry Chow; Steven Stratton; Sylvan Green; Yrma Obregon; Irene Alvarez; Michael Gordon
Journal:  Am J Clin Oncol       Date:  2008-04       Impact factor: 2.339

Review 9.  The importance of balanced pro-inflammatory and anti-inflammatory mechanisms in diffuse lung disease.

Authors:  Michael P Keane; Robert M Strieter
Journal:  Respir Res       Date:  2001-10-15

10.  Are risk factors associated with outcomes in pancreatic cancer?

Authors:  De-shen Wang; Zhi-qiang Wang; Le Zhang; Miao-zhen Qiu; Hui-yan Luo; Chao Ren; Dong-sheng Zhang; Feng-hua Wang; Yu-hong Li; Rui-hua Xu
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

View more
  14 in total

Review 1.  Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification.

Authors:  Archana Bhaw-Luximon; Dhanjay Jhurry
Journal:  J Cancer Res Clin Oncol       Date:  2016-05-09       Impact factor: 4.553

2.  The Presence of Interleukin-13 at Pancreatic ADM/PanIN Lesions Alters Macrophage Populations and Mediates Pancreatic Tumorigenesis.

Authors:  Geou-Yarh Liou; Ligia Bastea; Alicia Fleming; Heike Döppler; Brandy H Edenfield; David W Dawson; Lizhi Zhang; Nabeel Bardeesy; Peter Storz
Journal:  Cell Rep       Date:  2017-05-16       Impact factor: 9.423

3.  Orthotopic inflammation-related pancreatic carcinogenesis in a wild-type mouse induced by combined application of caerulein and dimethylbenzanthracene.

Authors:  Chen Liang; Zhen Wang; Li Wu; Chen Wang; Bao-Hua Yu; Xiu-Zhong Yao; Xiao-Lin Wang; Ying-Yi Li
Journal:  Tumour Biol       Date:  2015-04-29

4.  Incidence and Risk of Pancreatic Cancer in Patients with a New Diagnosis of Chronic Pancreatitis.

Authors:  Satish Munigala; Divya S Subramaniam; Dipti P Subramaniam; Thomas E Burroughs; Darwin L Conwell; Sunil G Sheth
Journal:  Dig Dis Sci       Date:  2021-02-25       Impact factor: 3.199

5.  Inflammatory macrophages in pancreatic acinar cell metaplasia and initiation of pancreatic cancer.

Authors:  Geou-Yarh Liou; Peter Storz
Journal:  Oncoscience       Date:  2015-03-28

6.  Extrinsic intestinal denervation modulates tumor development in the small intestine of Apc(Min/+) mice.

Authors:  Verena Liu; Alexandra Dietrich; Michael S Kasparek; Petra Benhaqi; Marlon R Schneider; Michael Schemann; Hendrik Seeliger; Martin E Kreis
Journal:  J Exp Clin Cancer Res       Date:  2015-04-29

Review 7.  Targeting NK-1 Receptors to Prevent and Treat Pancreatic Cancer: a New Therapeutic Approach.

Authors:  Miguel Muñoz; Rafael Coveñas
Journal:  Cancers (Basel)       Date:  2015-07-06       Impact factor: 6.639

8.  Cytokine patterns in brain tumour progression.

Authors:  Radu Albulescu; Elena Codrici; Ionela Daniela Popescu; Simona Mihai; Laura Georgiana Necula; Daniel Petrescu; Mihaela Teodoru; Cristiana Pistol Tanase
Journal:  Mediators Inflamm       Date:  2013-06-24       Impact factor: 4.711

Review 9.  Oncolytic viral therapy for pancreatic cancer: current research and future directions.

Authors:  Justin W Ady; Jacqueline Heffner; Elizabeth Klein; Yuman Fong
Journal:  Oncolytic Virother       Date:  2014-02-17

10.  Inactivation of the Euchromatic Histone-Lysine N-Methyltransferase 2 Pathway in Pancreatic Epithelial Cells Antagonizes Cancer Initiation and Pancreatitis-Associated Promotion by Altering Growth and Immune Gene Expression Networks.

Authors:  Guillermo Urrutia; Thiago Milech de Assuncao; Angela J Mathison; Ann Salmonson; Romica Kerketta; Atefeh Zeighami; Timothy J Stodola; Volkan Adsay; Burcin Pehlivanoglu; Michael B Dwinell; Michael T Zimmermann; Juan L Iovanna; Raul Urrutia; Gwen Lomberk
Journal:  Front Cell Dev Biol       Date:  2021-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.